Epsilon M&A Deal Report - Xellia Group (Xellia Pharmaceuticals)
Transaction Multiples for the Valuation of Private Companies
Private Group led by Novo A/S > Xellia Group (Xellia Pharmaceuticals)
Announced Date : 21 May 2013
Type : SBO (Secondary Buy Out) ,Exit
Deal Value : Yes
Acquirer : Private Group led by Novo A/S
Target Xellia Group (Xellia Pharmaceuticals)
Target Country Norway
Sector of activity : Health, Pharmaceuticals & Biotechnology
> Xellia Pharmaceuticals AS is a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, with over 100 years of experience and experti ...
Transaction multiples available
| EV/Sales | EV/Gross Profit | EV/EBITDA | EV/EBIT | Eq/PBT | P/E | Price to Book | |
|---|---|---|---|---|---|---|---|
| Historic | |||||||
| Current |
: Multiple available
n.s : Multiple calculated, but not significant
Rating **
Source: Epsilon Research / EMAT
Comparable Transactions
Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1226
Example of comparable transactions on EMAT (same sub-sector):
| Date | Acquirer | Target | Country | Multiples | See details |
|---|---|---|---|---|---|
| 30/09/2013 | Aspen Pharmacare Holdings | Fraxiparine and Arixtra brands of GSK and Associated Manufacturing Plant | France | 0 |
|
| 22/05/2013 | Private Group led by Charterhouse Capital Partners LLP | DOC Generici | Italy | 0 |
|
Source: Epsilon Research / EMAT
This report is accessible on EMAT, the reference database for private company acquisition multiples
Example of EMAT Report : click here
View Complete ReportEpsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.
Sectors covered by our analysts
Studies & indices published by Epsilon Research Register to receive (free) publications updates
Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).
Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.
Subscribe to EMAT database
